Clinical Trials Logo

Clinical Trial Summary

This pilot clinical trial studies how well metformin hydrochloride works in affecting cytokines and exosomes in patients with head and neck cancer. Metformin hydrochloride may reduce the metabolic activity of cancer cells and of surrounding supportive tissues.


Clinical Trial Description

PRIMARY OBJECTIVES: I. To assess the capacity of metformin hydrochloride (metformin) to alter the cytokine and exosome profiles. II. To assess the capacity of metformin to mitigate known side effects of external beam radiation therapy including inflammation, mucositis, dysphagia, xerostomia, and fatigue. SECONDARY OBJECTIVES: I. Assess safety and tolerability of metformin treatment in subjects undergoing external beam radiation treatment for head and neck cancer. II. To determine the effect of metformin treatment on symptoms of xerostomia as assessed by the Xerostomia Questionnaire (XQ). III. To determine the effect of metformin treatment on symptoms of mucositis as assessed by World Health Organization (WHO) classification. IV. To determine the effect of metformin treatment on symptoms of dysphagia as assessed by the MD Anderson Dysphagia Inventory. V. To determine the effect of metformin treatment on symptoms of fatigue as assess by the Multidimensional Fatigue Inventory (MFI). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03109873
Study type Interventional
Source Thomas Jefferson University
Contact
Status Completed
Phase Early Phase 1
Start date January 5, 2017
Completion date July 31, 2020

See also
  Status Clinical Trial Phase
Completed NCT05746780 - Bilateral Elective Neck Dissection in Salvage Total Laryngectomy
Active, not recruiting NCT03529422 - Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN Phase 2
Completed NCT02126969 - A Study of Chemo +/- Low-dose Radiation as Induction Therapy in SCCHN Phase 2
Completed NCT01263873 - Examining the Ease of Intubation Using the Parker Flex-Tip® or a Standard Endotracheal Tube N/A
Completed NCT03162731 - Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer Early Phase 1
Enrolling by invitation NCT03269396 - Laryngeal Allograft Transplantation N/A
Completed NCT01649973 - Study for Appropriate Operating Table Height for Endotracheal Intubation Under Direct Laryngoscopy N/A
Withdrawn NCT04168671 - CLE During Exercise Testing in Asthma N/A
Completed NCT01321892 - Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium N/A
Recruiting NCT05636410 - Ultrasound Assessment of the Larynx and Trachea in the Neonatal Period
Recruiting NCT05565430 - Vocal Cord Responses During Hyperventilation in Normal Individuals and in Mild and Severe Asthmatics.
Active, not recruiting NCT03737968 - Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients. Phase 2
Recruiting NCT03109171 - Accuracy of the Sensory Test Using the Laryngopharyngeal Endoscopic Esthesiometer in Obstructive Sleep Apnea N/A
Completed NCT02761239 - Innervation of Human Cricopharyngeal Muscle By Recurrent Laryngeal and External Branch of Superior Laryngeal Nerve N/A
Recruiting NCT05145556 - Teach Intubation by Novices in Anaesthesiology N/A
Completed NCT03030781 - Relationship of Cricoid With the Right and Left Bronchial Diameters in the Pediatric Population Using Three-dimensional Imaging. N/A
Completed NCT03238365 - Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck Early Phase 1
Withdrawn NCT02065128 - The Efficacy of Capsaicin Sensitivity Testing in Patients With Irritable Larynx Syndrome N/A
Active, not recruiting NCT03854032 - Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck Phase 2
Active, not recruiting NCT03076281 - Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Phase 2